• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    IDrugs : the investigational drugs journal

    IDrugs : the investigational drugs journal

    JournalISSN 1369-7056eISSN 2040-3410

    年发文量

    研究主题

    论文(2700)

    排序
    1Alzheimer's Disease Drug Discovery--11th International Conference--Targeting Pathological Tau. 27-28 September 2010, Jersey City, NJ, USA.
    Michael S Wolfe

    The 11th Alzheimer's Disease Drug Discovery International Conference, held in Jersey City, NJ, USA, included topics covering new therapeutic developments in the field of Alzheimer's disease. This conference report highlights selected presentations on targeting pathological tau for the prevention or treatment of Alzheimer's disease. Investigational approaches discussed include aminothienopyridazine inhibitors of tau aggregation, the alternative splicing of tau pre-mRNA, protein phosphatase 2A as a potential therapeutic target, and immunotherapy and macroautophagy approaches for clearing aberrant tau protein from the brain.

    2010引用:1
    引用
    AI阅读
    加入学术空间
    2Hdac Inhibitors - Chi'S Third Annual Conference 2-3 November 2009, Boston, Ma, Usa
    Roberto R. Rosato

    The HDAC Inhibitors meeting, held in Boston, included topics covering new therapeutic developments in the field of HDAC inhibitors. This conference report highlights selected presentations on HDAC inhibitors for the treatment of cancer, inflammation, and neurodegenerative and other CNS diseases. Investigational drugs discussed include several compounds under evaluation by Karus Therapeutics Ltd, OCID-4681 (Orchid Research Laboratories Ltd) and EVP-0334 (EnVivo Pharmaceuticals Inc).

    2010
    引用
    AI阅读
    加入学术空间
    3Natural Peptides to Drugs - Fourth International Congress 11-14 April 2010, Zermatt, Switzerland
    Andrea Leone-Bay

    The Natural Peptides to Drugs congress, held in Zermatt, Switzerland, included topics covering new therapeutic developments in the field of peptide-and protein-based drugs derived from natural products. This conference report highlights selected presentations on drug discovery from natural peptides, natural peptide-based drugs in preclinical and clinical development, and peptide candidates. Investigational drugs discussed include novel small peptides from KAI Pharmaceuticals Inc, XEP-018 (Atheris Laboratories), MKC-253 (MannKind Corp), AEZS-108 (AEterna Zentaris Inc) and XG-102 (Auris Medical AG/Xigen SA).

    2010
    引用
    AI阅读
    加入学术空间
    428Th Annual Jpmorgan Healthcare Conference Exelixis and Nektar Therapeutics 11-14 January 2010, San Francisco, Ca, Usa
    Sophie Gale,Gary Croasdell

    The JPMorgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing their achievements in 2009 and expectations for 2010. This conference report highlights presentations from Exelixis Inc and Nektar Therapeutics. Investigational drugs from Exelixis, including XL-184 (in collaboration with Bristol-Myers Squibb Co), XL-147 and XL-765 (both in collaboration with sanofi-aventis), and from Nektar, including NKTR-118 and NKTR-119 (both now licensed to AstraZeneca plc), NKTR-171, NKTR-181, NKTR-194, NKTR-102, and NKTR-105, are discussed.

    2010
    引用
    AI阅读
    加入学术空间
    5ADMET--Fifth Annual SMi Conference.
    John E Comer

    SMi's fifth annual ADMET Conference, held in London, included topics covering new developments in the field of ADMET. This conference report highlights selected presentations on ADME optimization in drug discovery; targeting drugs to the brain; predicting bonds that might be attacked during metabolism; treating Caco-2 membranes with vinblastine to enhance P-glycoprotein interactions; predictive ADMET in hit-to-lead optimization; structure-based studies of ADMET targets; an accelerated process for integrated drug development; building hypotheses in lead selection and optimization; supersaturation effects; the prediction of drug-drug interactions; developing a mechanism-based pharmacokinetic/pharmacodynamic model; drug transporter assays in drug discovery; time-dependent inhibition screens in early drug discovery; the system-dependent inhibition of CYP enzymes; the integrating predictive toxicology framework OpenTox; high-content analysis for predictive cytotoxicity testing; and emerging in vitro toxicity assays.

    2010引用:22
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 2700 篇论文

    高被引作者

    作者引用发文
    Norman Peter50424
    David Rotella43720
    David P. Rotella36520
    S Shah34820
    Daniel Baty3431
    Patrick Chames3431
    Susman Edward31915
    Marie-Christine Buhot3111
    Worker C31012
    McKinnon C30313

    高产作者

    作者引用发文
    Claire Veryard27527
    Norman Peter50424
    David Rotella43720
    David P. Rotella36520
    S Shah34820
    Sophie Gale23718
    G. Croasdell21716
    Kibble Alexandra18516
    Vicki L. Mason14016
    Searle Ben18415

    相关期刊

    Medicinal Research Reviews
    Annual reports in medicinal chemistry
    Drug news & perspectives